Buspirone (Buspar) vs Wellbutrin: Which Is Better for Anxiety?

The names are similar enough to cause confusion at the pharmacy. The clinical difference is significant enough to matter a great deal.

Buspirone and bupropion (Wellbutrin) both appear on lists of medications used for anxiety. But they occupy very different positions in that treatment landscape, and prescribing one when the other is indicated is a genuine clinical error that delays recovery.

What This Page Covers

• How buspirone works and what it is approved for
• How Wellbutrin works and what it is approved for
• Clinical evidence for each in anxiety treatment
• Key differences in side effects, onset, and patient fit
• When the combination makes sense
• How to talk to your prescriber about the right option

Buspirone: What It Is and How It Works

Buspirone is an anxiolytic medication in the azapirone drug class. It was initially developed as an antipsychotic, but its antipsychotic activity was insufficient while its anxiolytic properties were notable. The FDA approved buspirone for the management of generalized anxiety disorder in 1986, and generic buspirone has been available since 2001.

The mechanism is specific and clinically meaningful. Buspirone works as a partial agonist at postsynaptic serotonin 5-HT1A receptors and a full agonist at presynaptic 5-HT1A autoreceptors in the dorsal raphe. Initially, this reduces serotonin neuron firing. Over 2 to 4 weeks, the autoreceptors desensitize, leading to increased serotonin release and enhanced serotonergic tone in brain regions involved in anxiety regulation.

Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding. This is why it does not produce sedation, physical dependence, or withdrawal symptoms when stopped, and why it does not block benzodiazepine withdrawal if a patient is transitioning off benzos.

The standard starting dose for GAD is 7.5 mg twice daily, typically titrated up to 15 to 30 mg per day. The full therapeutic effect requires 4 to 6 weeks.

Buspirone Clinical Evidence

Controlled clinical trials have established buspirone as effective for generalized anxiety disorder. The FDA clinical trial database for buspirone includes a study of 6,632 patients with outcomes demonstrating consistent anxiety relief across age groups without significant safety concerns.

Buspirone has also been studied as an augmentation agent for depression. The STAR*D trial, a large-scale study of over 2,800 patients, examined buspirone augmentation of citalopram after initial SSRI failure and found remission rates of approximately 30% on the Hamilton Depression Rating Scale, comparable to augmentation with sustained-release bupropion. This finding supports a role for buspirone in treatment-resistant depression scenarios involving co-occurring anxiety.

The drug does not work immediately. Patients who have previously used benzodiazepines for anxiety may find it less effective, because buspirone’s mechanism does not cross-tolerate with benzo-conditioned expectations. It is better suited for benzodiazepine-naive patients or those who have already completed benzodiazepine tapering.

Wellbutrin: What It Is and How It Works

Bupropion, sold under brand names including Wellbutrin and Forfivo XL, is classified as an atypical antidepressant. Unlike SSRIs, which primarily target serotonin, bupropion is a norepinephrine and dopamine reuptake inhibitor (NDRI). It blocks the reuptake of both neurotransmitters, increasing their synaptic availability.

This mechanism produces an activating, energizing effect that is clinically useful for depression with prominent fatigue, low motivation, and cognitive slowing. It also supports smoking cessation, an FDA-approved indication, because nicotinic acetylcholine receptor antagonism reduces cravings.

Wellbutrin is FDA-approved for major depressive disorder, seasonal affective disorder, and smoking cessation. It is not FDA-approved for anxiety disorders. Any use for anxiety is off-label.

Why Wellbutrin for Anxiety Requires Caution

The activating mechanism that makes Wellbutrin useful for low-energy depression is the same mechanism that can worsen anxiety in susceptible patients. Clinical trial data show that 5 to 6 percent of bupropion trial participants reported increased anxiety compared to 3 percent on placebo.

Patients whose anxiety is characterized by physical tension, hyperarousal, racing thoughts, or an already over-active nervous system may find that Wellbutrin amplifies rather than reduces their baseline anxiety state.

This does not mean Wellbutrin is never useful in anxiety. When anxiety is comorbid with depression, particularly depression featuring fatigue, low motivation, or low mood alongside secondary anxiety, Wellbutrin addresses the primary depressive picture and may indirectly reduce anxiety as mood improves. But it is not a primary anxiolytic, and prescribing it as such when buspirone or an SSRI is more appropriate reflects a mismatch between mechanism and clinical target.

Side Effect Comparison

The side effect profiles differ in clinically significant ways.

Buspirone’s most common early effects include dizziness (occurring in more than 10% of patients), nausea, headache, and nervousness, most of which diminish within one to two weeks of initiation. It does not cause sexual dysfunction, weight gain, sedation, or cognitive impairment. It is not a controlled substance.

Wellbutrin’s side effects include insomnia, headache, dry mouth, nausea, and elevated blood pressure. More importantly, it carries an elevated seizure risk, particularly at higher doses. It is contraindicated in patients with a history of seizures, eating disorders such as bulimia or anorexia, or heavy alcohol use. It can cause weight loss in some patients, which may be therapeutically useful or may be a side effect depending on baseline weight and goals. Sexual side effects are lower with Wellbutrin than with SSRIs.

Which Medication Fits Which Patient

Buspirone is the stronger clinical fit when the primary diagnosis is generalized anxiety disorder, the patient has no history of seizures or eating disorders, the patient is benzodiazepine-naive or has already completed a taper, and sexual side effects, sedation, or dependence risk are primary concerns.

Wellbutrin is a stronger clinical fit when depression is the primary diagnosis with fatigue and low motivation as core features, the patient has sexual side effects from SSRIs and wants an alternative without that profile, the patient is working on smoking cessation alongside mood treatment, or there is clinical judgment that the activating effect will be therapeutic rather than destabilizing for this individual.

The combination of both medications is sometimes used when anxiety and depression are co-presenting and each medication addresses a different component of the clinical picture.

About SiggyMD

Choosing between medications for anxiety and depression requires more than comparing a side-effect list. It requires understanding your full symptom picture, what you’ve tried before, and how your biology responds over time.

SiggyMD’s anonymous intake process gathers structured clinical information about your anxiety and depression symptoms before any medication is prescribed. Your care team reviews this data before making any recommendation. After treatment begins, daily check-ins track how symptoms actually respond, not how you remember feeling at a quarterly appointment.

“The buspirone versus Wellbutrin question comes up often,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “The mechanism difference is real, and prescribing one when the patient’s clinical picture calls for the other delays recovery. I use the intake data and daily tracking to make sure the medication we choose actually fits the patient, not just the category on paper.”

Neither buspirone nor Wellbutrin is a controlled substance, and both are available through SiggyMD’s care pathway where clinically appropriate.

The anonymous intake requires no name, email, or account. A licensed prescriber reviews every treatment plan.

For more on related topics, see our posts on anxiety medication timelines and anti-anxiety medication side effect profiles. For context on how SSRIs compare, see SSRI medications compared.

Start your anonymous intake with SiggyMD to discuss which anxiety medication makes clinical sense for your specific situation.

What Members Are Saying

TH

T.H., 33

Generalized Anxiety Disorder

“My previous provider prescribed Wellbutrin for anxiety. It made me feel wired and more anxious. When my SiggyMD prescriber explained why, and switched to buspirone with a plan for what to expect over the first six weeks, everything changed. Understanding the mechanism helped me stick with it long enough to actually work.”

SP

S.P., 45

Depression with Anxiety

“Taking both together seemed counterintuitive at first. But after my prescriber explained that Wellbutrin was addressing my depression and motivation while buspirone was specifically targeting the anxiety, I understood why they work together. The daily check-in data helped us tune the combination over time.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment information.

If you are in crisis or experiencing thoughts of self-harm, call or text 988. If you are in immediate danger, call 911.

Sources

1. Landy K, Rosani A, Estevez R. Buspirone. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2026.

2. U.S. Food and Drug Administration. BuSpar (buspirone HCl) Prescribing Information. FDA; 2010.

3. GoodRx. Buspirone vs. Wellbutrin XL for Anxiety and Depression. Accessed June 2026.

4. Blossom Health. Buspirone vs. Bupropion: What’s the Difference? Accessed June 2026.

5. Wikipedia contributors. Buspirone. Wikipedia. Accessed June 2026.

6. PsychWiki. Buspirone (BuSpar). Accessed June 2026.

7. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. STAR*D trial outcomes referenced in StatPearls buspirone monograph. New England Journal of Medicine. 2006.